Lilly's Verzenio Demonstrates Significant Reduction in Recurrence Risk for Early Breast Cancer, Driving $21 Billion Surge in Market Cap

On June 16, Eli Lilly announced that the prespecified interim analysis of the Phase III monarchE study had met its primary endpoint. Verzenio (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) significantly improved invasive disease-free survival (IDFS) compared with standard adjuvant endocrine therapy alone, substantially reducing the risk of disease recurrence or death. Verzenio is currently the only CDK4/6 inhibitor clinically proven to significantly reduce the risk of recurrence in patients with high-risk, HR+, HER2- early breast cancer.

Following Pfizer’s announcement on May 29 that its Phase III PALLAS study of the CDK4/6 inhibitor Ibrance (palbociclib) in combination with adjuvant endocrine therapy for HR+/HER2- breast cancer was unlikely to meet the primary endpoint of invasive disease-free survival (iDFS), Eli Lilly’s stock price surged 16% on June 17, adding approximately $21 billion to its market capitalization.

monarchE is a multicenter, randomized, open-label, Phase III study that enrolled 5,637 patients with high-risk, node-positive, hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) early breast cancer. Patients were randomized in a 1:1 ratio to receive Verzenio (150 mg twice daily) in combination with standard adjuvant endocrine therapy or standard adjuvant endocrine therapy alone. Patients in the Verzenio arm received abemaciclib for up to 2 years or until meeting discontinuation criteria, while all patients received at least 5 years of standard endocrine therapy. The primary endpoint was invasive disease-free survival (IDFS), defined as the time from randomization to any cancer recurrence or death. Secondary endpoints included recurrence-free survival, overall survival, safety, pharmacokinetics, and health outcomes.

The monarchE study is expected to be completed in June 2027. This interim analysis considers the invasive disease-free survival (IDFS) results to be definitive. Researchers will continue to follow up with all patients in the monarchE trial to assess overall survival and other endpoints. Eli Lilly plans to present these data at a medical conference later this year.

Maura Dickler, Vice President and Head of Late-Stage Development in Oncology at Eli Lilly, stated, “When individuals are diagnosed with high-risk early-stage breast cancer, they do everything possible to prevent recurrence. As clinicians, we share the same goal. The monarchE trial was specifically designed for patients with breast cancer at high risk of recurrence. We are highly encouraged by the results from monarchE, which may provide a new treatment option for patients with high-risk, HR+, HER2- early-stage breast cancer.”

Anne White, President of Lilly Oncology, stated, “Verzenio has already provided treatment to hundreds of thousands of patients worldwide with HR+, HER2- advanced breast cancer. Now, Verzenio in combination with endocrine therapy has demonstrated positive results in patients with high-risk HR+, HER2- early breast cancer, marking a significant milestone that has the potential to change the practice of treating early breast cancer. We are also very excited to obtain these results early in the interim analysis, as this will help us bring innovative therapies to those in need as soon as possible. We look forward to submitting these data to regulatory authorities by the end of 2020.”

Breast cancer is the most common cancer among women worldwide, with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer being the most prevalent subtype, accounting for approximately 70% of cases. Patients with this subtype are typically treated with endocrine therapy; however, treatment efficacy is limited by the development of resistance and disease recurrence. HR+/HER2- breast cancer is a complex disease, and various factors—such as lymph node involvement and tumor biological characteristics—contribute to an elevated risk of recurrence. Approximately 30% of patients with early-stage HR+/HER2- breast cancer progress to recurrent or metastatic disease, which is difficult to cure.

CDK4/6 are key regulators of the cell cycle, triggering the transition from the growth phase (G1 phase) to the DNA synthesis phase (S phase). CDK4/6 inhibitors arrest the cell cycle at the G1 phase, thereby inhibiting tumor cell proliferation. The emergence of CDK4/6 inhibitors has transformed treatment outcomes for patients with HR+/HER2- breast cancer, effectively overcoming or delaying the onset of endocrine resistance and extending patient survival.

Currently, the three CDK4/6 inhibitors approved globally are indicated for patients with advanced or metastatic HR-positive, HER2-negative breast cancer, whether used in combination with endocrine therapy or as monotherapy, and whether as first-line or second-line treatment. Verzenio has now demonstrated in clinical trials that it can reduce the risk of recurrence in patients with early-stage HR-positive, HER2-negative breast cancer, thereby addressing a broader patient population. This will undoubtedly help Eli Lilly capture a larger market share in this high-demand therapeutic area.